Table 3 –

Covariate-adjusted meta-regression comparing efficacy and toxicity between salvage modalities and radical prostatectomy

	2-yr RFS	5-yr RFS	Severe GU toxicity	Severe GI toxicity
Radical prostatectomy
Adjusted percenta (95% CI)	72% (66–78%)	53% (46%–59%)	21% (16%–26%)	1.5% (0.4%–3.2%)
Odds ratio (95% CI)	1.0	1.0	NA	NA
p value	Reference	Reference	Reference	Reference
R2 (%)	0.0	0.0	0.0	0.0
Cryotherapy
Adjusted percenta (95% CI)	66% (59–72%)	57% (49–65%)	15% (8–23%)	0.9% (0.3–1.8%)
Odds ratio (95% CI)	0.74 (0.49–1.12)	1.20 (0.80–1.79)	NA	NA
p value	0.2	0.4	0.2	0.5
R2 (%)	25	0.0	8.2	27
HIFU
Adjusted percenta (95% CI)	52% (45%–59%)	46% (37%–55%)	23% (17%–30%)	0.8% (0.1%–2.1%)
Odds ratio (95% CI)	0.42 (0.28–0.64)	0.76 (0.48–1.21)	NA	NA
p value	<0.001	0.2	0.5	0.4
R2 (%)	0.0	41	15	22
SBRT
Adjusted percenta (95% CI)	58% (46–69%)	56% (37–73%)	5.6% (1.4–12%)	0.0% (0.0–1.2%)
Odds ratio (95% CI)	0.52 (0.30–0.93)	1.13 (0.50–2.58)	NA	NA
p value	0.03	0.8	<0.001	0.07
R2 (%)	55	4.2	0.00	0.0
HDR
Adjusted percenta (95% CI)	77% (69–83%)	58% (52–64%)	9.6% (6.0–13.9%)	0.0% (0.0–0.3%)
Odds ratio (95% CI)	1.26 (0.77–2.09)	1.25 (0.88–1.78)	NA	NA
p value	0.4	0.2	0.002	0.003
R2 (%)	0.0	91	0.0	0.0
LDR
Adjusted percenta (95% CI)	79% (72–85%)	53% (43–63%)	9.1% (5.2–14%)	2.1% (0.6–4.0%)
Odds ratio (95% CI)	1.49 (0.89–2.50)	1.02 (0.63–1.67)	–	–
p value	0.13	0.9	0.001	0.6
R2 (%)	4.3	5.2	12	20%

CI = confidence interval; GI = gastrointestinal; GU = genitourinary; HDR=high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDR=low-dose-rate brachytherapy; NA = not available; RFS = recurrence-free survival; SBRT = stereotactic body radiotherapy.

Significant p-values after Bonferroni correction appear in bold.

^aBack-transformed regression coefficients for ease of interpretation.